This article is more than 5 years old. Information may no longer be current.

ReGenTree initiates phase 3 dry eye treatment trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ReGenTree has begun a phase 3 clinical trial of RGN-259 eye drops for the treatment of dry eye syndrome, the company announced in a press release.

The double-masked, placebo-controlled, randomized ARISE-3 trial will compare the safety and efficacy of RGN-259 0.1% compared with placebo in the treatment of signs and symptoms of dry eye. It will include 700 patients at 15 U.S. sites.

RGN-259, which the company says has “wide-ranging protective, repair and regenerative activities,” includes the active small protein thymosin beta 4, which is in naturally occurring tears.

ReGenTree is a joint venture company owned by GtreeBNT and RegeneRx Biopharmaceuticals. It was formed specifically to develop RGN-259.